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Abstract
In recent years, genome wide association studies have discovered a large number of gene loci that play a functional role in
innate and adaptive immune pathways associated with leprosy susceptibility. The immunological control of intracellular
bacteria M. leprae is modulated by NOD2-mediated signaling of Th1 responses. In this study, we investigated 211 clinically
classified leprosy patients and 230 ethnically matched controls in Indian population by genotyping four variants in NOD2
(rs9302752A/G), LRRK2 (rs1873613A/G), RIPK2 (rs40457A/G and rs42490G/A). The LRRK2 locus is associated with leprosy
outcome. The LRRK2 rs1873613A minor allele and respective rs1873613AA genotypes were significantly associated with an
increased risk whereas the LRRK2 rs1873613G major allele and rs1873613GG genotypes confer protection in paucibacillary
and leprosy patients. The reconstructed GA haplotypes from RIPK2 rs40457A/G and rs42490G/A variants was observed to
contribute towards increased risk whereas haplotypes AA was observed to confer protective role. Our results indicate that a
possible shared mechanisms underlying the development of these two clinical forms of the disease as hypothesized. Our
findings confirm and validates the role of gene variants involved in NOD2-mediated signalling pathways that play a role in
immunological control of intracellular bacteria M. leprae.
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Introduction
Leprosy is a chronic infectious disease of the skin and nerves,
caused by the bacterium Mycobacterium leprae. Despite decreased
prevalence in last two decades, the number of new case detection
rates remains high as far as in 130 countries, with India
contributing to half of the new cases detected worldwide [1].
Host immune responses [2,3] and genetic factors had been shown
to influence the clinical spectrum of leprosy [4–7]. Most notable is
inter individual variability in disease development, with a wide
range of manifestations ranging from lepromatous to tuberculoid
leprosy [8]. The lepromatous leprosy is distinguished as borderline
lepromatous (BL) and lepromatous (LL) forms and is classified as
multibacillary (MB) based on the bacillary load, whereas the
tuberculoid leprosy is distinguished as tuberculoid (TT) and
borderline tuberculoid (BT) and are classified as paucibacillary
(PB) by WHO standards. A difference in immune responses
between multibacillary and paucibacillary forms are predicted. In
multibacillary or lepromatous forms, the absence of Th1 responses
increases the bacilli load with strong humoral immunity [4]. On
the other hand, the paucibacillary or the tuberculoid forms reveal
an increased Th1 response with limited bacterial load.
The intracellular M. leprae has an extended incubation period
for up to 30 years. The pathogen driven selection can
potentially alter the primed sequence and can direct to
substantial changes in gene expression [9]. The pathogen
recognition receptors such as TLRs (Toll-like receptors) ably
recognize the microbes at cell surfaces, whereas PRRs such as
nucleotide oligomerization domain (NOD) like receptors that are
localized in the cytosol can sense and recognize the intracellular
pathogens [10]. A recent genome wide study in Chinese leprosy
patients has provided vital insights on the role of NOD2
(rs9302752A/G), LRRK2 (rs1873613A/G) and RIPK2
(rs40457A/G and rs42490G/A) variants in regulating the
leprosy infection [7]. In addition, the expression of these genes
has been shown to up regulate in leprosy in comparison to
normal tissues [11]. The Nucleotide-binding oligomerization
domain 2 (NOD2) located on the long arm of chromosome 16
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(16q21) is an intracellular microbial sensor for muramyl
dipeptide, a component of bacterial peptidoglycan [12].
Dysregulation in NOD2 signalling is associated with pathogenesis
of many inflammatory disorders [13] and is also associated with
triggering of IL-32 dependent dendritic cell programming in
leprosy [14]. The cytosolic pattern recognition receptor NOD1
and NOD2 also activates the RIPK2 gene [15]. The gene
encoding receptor- interacting serine-threonine kinase 2 (RIPK2)
located on the long arm of chromosome 8 (8q21) is essential for
signaling through the Toll-like receptors [15,16]. In addition,
the RIPK2 interaction with NOD2 enhances NF-kB activity
making it an important player in cellular immune response [17].
The Leucine-rich repeat serine/threonine-protein kinase 2
(LRRK2) variants located on the long arm of chromosome 12
(12q12) are well documented as a common cause for parkinson
disease [18]. Also LRRK2 gene variants were also documented
for their role in inflammatory diseases [19] and to microbial
infections [20,21]. During onset of early leprosy infection, M.
leprae antigens are presented to CD4+T cells, which activate the
Th1 responses resulting in interferon gamma production leading
to macrophages maturation and subsequent killing. NOD2 and
RIPK2 regulate the interferon- gamma production [7].
Initiation of NOD2 signalling is mediated by RIPK2 by an
ubiqutination process and involvement of TAK1 and nuclear
factor-kB essential modulator to the NOD2-RIPK2 complex leads
to the movement of NF-kB to the nucleus and subsequent
activation of NF-kB target genes [22]. NOD2-mediated signaling
pathway plays an essential role in the immunological control of
intracellular bacteria. We investigated the possible association of
gene variants NOD2 (rs9302752A/G), LRRK2 (rs1873613A/G)
and RIPK2 (rs40457A/G and rs42490G/A) that are vital for
NOD2 signalling and subsequent activation of the NF-kB complex
in a cohort of clinically classified leprosy patients.
Materials and Methods
Ethical Statement
Informed written consent was received from all leprosy patients.
The study was approved by the research advisory committee and
institutional ethical committee of LEPRA- Blue peter public health
research centre, Hyderabad, India. Informed written consent was
also obtained from all the normal individuals and the institutional
ethical committee of CCMB has approved this study.
Sampling
All the leprosy patients studied (n= 211) were outpatients and
were recruited at the LEPRA- Blue Peter Public Health and
Research Centre (BPHRC) in Hyderabad, India [23]. Patients
were clinically evaluated and graded by the physicians either as a
paucibacillary (PB, n = 74) or multibacillary (MB, n= 137) group,
based on WHO standards [24]. Based on the number of lesions
and presence of acid-fast bacilli (AFB) in skin slit smears taken
from at least five different places of the body (both earlobes, both
halves of the forehead, at least one from one of the lesions) leprosy
patients were classified. More than five lesions as well as presence
of acid fast bacilli in any of the smears precludes a multibacillary
diagnosis, while a number of less than five lesions and, more
importantly, a lack of acid fast bacilli in any of the smears is
considered as the paucibacillary presentation. In addition to the
patients, blood samples from individual controls (n = 230) were
collected from adult males and females (18–35 years) form the
same ethnicity.
Genotyping
DNA was isolated from blood utilizing the DNeasy Blood and
Tissue kit (Qiagen, Germany) following the protocol of the
manufacturer. The primer sequences utilized for genotyping with
primer specific annealing temperatures is summarized in Table 1.
In brief: PCR was carried out in a 20 ml reaction volume with 5 ng
of genomic DNA, 16 PCR buffer (20 mM Tris-HCl pH 8.4,
50 mM KCl, 1.5 mM of MgCl2; Qiagen), 0.125 mM of dNTPs,
0.5 mM of each primer and 1 U Taq DNA polymerase (Qiagen,
Hilden, Germany) on a PTC-200 Thermal cycler (MJ Research,
USA). Thermal cycling parameters for amplification were: initial
denaturation at 94uC for 5 min, followed by 35 cycles of
respectively 15 sec at 94uC for denaturation, 60 sec at primer
specific annealing temperature, and 60 sec at 72uC extension. This
was followed by a final extension of 10 min at 72uC. PCR
products were cleaned up using Exo-SAP-IT (USB, Affymetrix,
USA) and 1 ml of the purified product were directly used as
templates for sequencing, using the BigDye terminator v. 2.0 cycle
sequencing kit (Applied Biosystems, USA) on an ABI 3130 XL and
ABI 37306L DNA sequencer, according to the manufacturer’s
instructions. Polymorphisms were identified by assembling the
sequences with respective reference sequences obtained from
SNPper database (http://snpper.chip.org) using Codon code
Aligner 4.0 software (http://www.codoncode.com/) and were
reconfirmed visually from their respective electropherograms.
Statistical Analysis
Data was analyzed using STATA and the level of significance
was set to a p-value of ,0.05. The distribution of genotypes
between control and leprosy patients, as well as between controls
and clinically classified patients were analyzed by two tailed fisher
exact tests. Genotype or haplotype frequencies were analyzed by
simple gene counting and expectation-maximum (EM) algorithm
and the significance of deviations from Hardy-Weinberg equilib-
rium was tested using the random-permutation procedure as
implemented in the Arlequin v. 3.5.1.2 software. (http://lgb.unige.
ch/arlequin). The comparison of Linkage disequilibrium (LD) for
RIPK2 variants for each patient group as well as for controls were
computed using the Haploview v4.2 software that utilizes a default
algorithm and this algorithm ignores markers with minor allele
frequencies (MAF) ,0.05.
Results
The observed distribution of genotypes and alleles in both
clinically classified patients and controls were summarized in
Table 2. The observed genotype and allele frequencies of all
studied SNPs in clinically classified patient groups and controls
were in Hardy-Weinberg equilibrium (P.0.05) except for the
NOD2 SNP rs9302752 (P,0.05). Therefore the NOD2 SNP
rs9302752 was excluded for further association analysis.
In LRRK2 gene locus, we observed that the minor allele LRRK2
rs1873613A and homozygous genotype rs1873613AA were more
frequent in leprosy patients than in controls conferring an
increased risk of leprosy (OR=1.7, 95% CI= 1.25–2.2,
P= 0.0003 and OR=2.04, 95% CI= 1.2–3.6, P = 0.007, respec-
tively). Whereas major allele LRRK2 rs1873613G and homozygous
genotype rs1873613GG were observed less frequently in patients
compared to controls conferring a decreased risk of leprosy
(OR=0.61, 95% CI=0.45–0.8, P= 0.0003 and OR=0.56, 95%
CI= 0.37–0.83, P= 0.0028, respectively). When clinically classi-
fied paucibacillary (PB) patients were compared to controls, a
similar trend was observed with a stronger significance (for the
minor allele rs1873613A: OR=2.77, 95% CI= 1.9–4.1,
Association of LRRK2 and RIPK2 SNPs with Leprosy
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P,0.0001; for the homozygous genotype rs1873613AA: OR=4.1,
95% CI=2.1–7.9, P =P,0.0001). These results may confer that
the LRRK2 rs1873613A/G contributed to the progression of
paucibacillary leprosy. However, there was no significant differ-
ence of allele and genotype frequencies in comparison to
multibacillary (MB) patients with controls (Table 2). In addition,
we did not observe any significant difference of heterozygous
genotype frequency in all comparisons.
Two loci of RIPK2 gene (rs40457A/G and rs42490G/A) were
investigated in this study. However, no significant difference of
allele and genotype frequency of neither SNP rs40457A/G or
rs42490G/A was observed in all the comparisons. In leprosy
patients, both the studied RIPK2 variants were observed to be in
high LD [Leprosy patients (D9=0.64, LOD=12.72, r2 = 0.2), MB
patients (D’ = 0.53, LOD=5.84, r2 = 0.56), PB patients (D9=0.84,
LOD=7.58, r2 = 0.34)], whereas in controls it was observed in a
low degree of linkage disequilibrium (D9=0.38, LOD=3.2,
r2 = 0.06)]. We reconstructed haplotype based on these two
studied RIPK2 SNPs (rs40457A/G and rs42490G/A). Four
haplotypes and their frequencies were observed including AG,
AA, GA and GG. The RIPK2 haplotype GA was observed more
frequently in leprosy patients compared to controls inferring an
increased risk of leprosy (OR=1.46, 95% CI= 1.02–2.1,
P = 0.036), whereas RIPK2 haplotype AA was observed less
frequently in leprosy patients compared to controls inferring a
protection against leprosy (OR=0.69, 95% CI= 0.49–0.97,
P = 0.028). In addition, RIPK2 haplotype GA was observed more
frequently in paucibacillary (PB) patients in comparison to controls
inferring an increased risk of leprosy (OR=1.8, 95% CI= 1.1–2.8,
P = 0.018). Furthermore, there was no significant difference of
RIPK2 haplotype frequencies in comparison between multi-
bacillary (MB) patients with controls (Table3).
Discussion
All the four studied innate immune gene variants were
hypothesized to play a significant role in controlling the
interferon-gamma production and considered as vital modulators
for NF-kB [7]. We investigated the role of gene variants in NOD2
(rs9302752A/G), LRRK2 (rs1873613A/G) and RIPK2 (rs40457A/
G and rs42490G/A) based on a recently published genome-wide
association study (GWAS) that utilized Han Chinese population
[7]. Although the studied sample size was lower, the frequencies of
all four studied variants were in accordance with Han Chinese
population and also in a Gujarati Indian population as reported in
HapMap database. The minor allele of NOD2 rs9302752A/G
variant was observed at a similar frequency (0.28) in the studied
Indian population to reported frequencies in Han Chinese
population (0.22). However, the NOD2 rs9302752A/G variant
was not in Hardy-Weinberg equilibrium in Indian clinically
classified leprosy patients and marginally significant in control
group. The major allele of LRRK2 rs1873613A/G variant was also
observed at a similar frequency (0.68) compared to reported
frequencies in Gujarati Indians in Houston, Texas (GIH) (0.61) as
reported in the NCBI Hapmap database. The minor allele of
studied RIPK2 variant rs40457A/G was observed at a similar
frequency (0.21) when compared to reported frequencies in Han
Chinese (0.25) and in Gujarati Indians in Houston, Texas (GIH)
(0.30), whereas the minor allele of RIPK2 rs42490A/G was
observed at a similar frequency (0.41) when compared to reported
frequencies in Han Chinese (0.45) and in Gujarati Indians in
Houston, Texas (GIH) (0.40).
NOD2 is an intracellular microbial sensor of the innate immune
system that can act as a potent activator and regulator of
inflammation in mycobacterial infections [10,25]. Mutations in the
gene encoding NOD2 in humans have been associated with
Crohn’s disease (CD) [26], Blau syndrome (BS) [27], and early
onset sarcoidosis (EOS) [28]. In addition, the studied NOD2
variant (rs9302752A/G) was associated with susceptibility to
tuberculosis and leprosy in Chinese and Vietnamese population
[7,29,30]. NOD2 signaling pathways are activated by a CARD
effector domain that causes inflammation by the activation of NF-
kB and MAP kinase pathways [10]. Studies have documented the
fact that stimulation of NOD proteins are associated with
enhanced pro inflammatory cytokine production to M. leprae
infections [31] and this is well achieved by the recognition of
conserved microbial domains by PRRs. Therefore, any alteration
in the gene function of PRR domain may possibly reflect towards
leprosy susceptibility. Also it was shown that phenotypes of mouse
deficient with NOD2 and RIPK2 revealed a failure to produce
inflammatory cytokines to initiate Th1 responses [32]. In contrast
to Han Chinese population [7] we observed that NOD2
rs9302752A/G variant was not in Hardy-Weinberg equilibrium
in studied Indian population, therefore the contribution of this
variant to leprosy susceptibility remains unclear. The possibilities
for the studied NOD2 variant not in HWE can be due to the fact
that Indian populations have been following strict endogamy
marriage practices for last tens of thousands years, hence every
population acquired unique set of genetic variations. In this study,
the leprosy patients represent different ethnic groups from south
India and the number from each group is very less. Nevertheless in
this study, we always employed ethnically matched control
individuals from the same population to avoid the role of
Table 1. Investigated SNP variants in leprosy patients and controls.
SNP ID Locus Gene SNP Primer Pairs (59–39) Tm [6C]
rs9302752 16q21 NOD2 A/G F: GCCTTTGTTTTCGCAGTTCCTTCAG 55
R: CCTCGGTGACCACTTCTCTGCATTC
rs1873613 12q21 LRRK2 A/G F: CACCCAAGACACACAAGGAAAAAGCATATA 55
R: GCCTTCTTACGTTTTACCTCCCCCTCTT
rs40457 8q21 RIPK2 A/G F: GATTTTCCCCCAGAAGAAGG 50
R: GCAGGAAAATGAATCCATGA
rs42490 8q21 RIPK2 G/A F: ACCCACTTCCTCCCTACCACAATCTG 55
R: GCGGAATAGCTGGATCTCTCACACA
doi:10.1371/journal.pone.0073103.t001
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population stratification in allelic difference between cases and
controls.
For the investigated LRRK2 rs1873613A/G variant the
contribution was observed of this particular variant in the studied
Indian population. The minor allele A and homozygous genotype
AA contributed towards an increased risk of leprosy whereas the
major allele G and homozygous genotype GG predisposed as
protective factors for leprosy. Our results also showed that LRRK2
rs1873613A/G variant significantly contributed to the develop-
ment of paucibacillary leprosy but not multibacillary leprosy.
Earlier studies have demonstrated that a trend towards an
association between the variant and susceptibility to leprosy [7].
The association study of LRRK2 rs1873613A/G variant with
leprosy was also conducted in a Vietnamese population, however
the association was not statistically significant [30]. LRRK2 is
associated with various diseases, including Parkinson’s disease,
cancer, and leprosy [33] and also known to be associated with
susceptibility to the chronic autoimmune Crohn’s disease, which is
an inflammatory disorder [34]. Higher expression of LRRK2 is
observed in macrophages and monocytes revealing its significance
in the innate immune system [35] and in leprosy per se. Most of
the replication studies do not document similar effects of a
particular gene variant contribution when investigated in different
ethnicities [36–38]. In the reported GWAS study from Han
Chinese population, the LRRK2 rs1873613A allele was observed as
a major allele whereas the rs1873613G variant is a minor allele and
confers decreased risk towards leprosy in Chinese patients. [7].
Additionally similar allele frequencies were reported in the
Vietnamese population [30]. However in the studied Indian
population, the LRRK2 rs1873613G allele was observed as a major
allele whereas the rs1873613A variant increased the risk towards
leprosy in the investigated Indian cohort. There seems a switch of
allele frequencies between populations and the clinical significance
of the studied variant likely depends on the context of the studied
ethnicities. Additionally India is inhabited by the very first out-of-
Africa modern human about 65,000 years ago. Since then they
remain unmixed, therefore the genome of Indian populations are
unique and the allele frequency differ significantly when compare
to the rest of the world [39]. LRRK2 gene has been shown to play
an important role in different diseases including Parkinson,
Crohn’s and inflammatory diseases [18,19,21,33]. Interestingly,
LRRK2 has been also demonstrated to be an IFN-gamma target
gene, involve in different immune response signaling such as NF-
kB pathways, and contribute to the antibacterial activity of the
macrophages, in which LRRK2 plays a role in the killing of
intracellular bacteria such as S. typhimurium [20]. In addition, the
expression of LRRK2 gene was significantly higher in leprosy
compared to normal tissues [11]. This suggested that LRRK2
might contribute crucially to the immune response against
intracellular bacteria M. leprae.
The RIPK2 rs40457A/G and rs42490G/A variants did not
confer any significance results at allele and genotype levels. A
larger sample size will be required in order to detect any
significance for the both studied RIPK2 variant at allele level.
We observed the reconstructed haplotypes AA and GA based on
two variants rs40457A/G and rs42490G/A to be significantly
associated with leprosy susceptibility. In addition, the haplotype
GA also conferred to an increased risk of paucibacillary leprosy
development. Recently, a replicate study conducted in a
Vietnamese population showed that the variant RIPK2
rs42490G/A was significantly associated with leprosy whereas
the significance was not revealed for the variant RIPK2 rs40457A/
G [30].Studies have established the fact that RIPK2 interaction
with NOD2 enhances NF-kB activity making it an important
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player in cellular immune response [17]. A recent study has also
documented on the interaction between the NOD2 and RIPK2 loci
(NOD2-RIPK2 complex) in activating the NF-kB pathway as a
part of the host defence response to leprosy infection [40].
Therefore, our results indicate that a possible shared mechanisms
as a basis for the development of these two clinical forms of the
disease as hypothesized earlier [7].
In conclusion, our study validated the association of gene
variants involved in intracellular sensing that are believed to play a
role in immunologic control of intracellular bacteria M. leprae in
Indian leprosy patients. Overall the study increases our under-
standing on complex molecular and cellular mechanisms that are
regulated by the intracellular pathogen M. leprae during its clinical
course.
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